Ipsen and Servier's hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cance
BeyondSpring's hopes of an early Christmas gift from the FDA were dashed today after the regulator said it was unable to approve the company's lead drug plinabulin as a treatment for low wh
After three brushes with cancer, Robert Weker understands the patient journey more than many – and he is determined to put that experience to good use.
